Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 773-792, October 2008

Adult-onset Still disease

  • Bruno Fautrel, MD, PhD (Professor)

      Affiliations

    • Corresponding Author InformationTel.: +33 1 421 77620; Fax: +33 1 421 77955.

Pierre & Marie Curie – Paris VI University/Paris Universitas, Department of Rheumatology, Pitié-Salpêtrière Hospital, 83 boulevard de l'Hôpital, 75651 Paris, Cedex 13, France

Adult-onset Still disease (AOSD) is an uncommon inflammatory condition of unknown origin typically characterized by four main (cardinal) symptoms: spiking fever ≥39°C, arthralgia or arthritis, skin rash and hyperleucocytosis (≥10,000cells/mm3) with neutrophils ≥80%. As many other manifestations are possible, diagnosis is potentially challenging. Determination of the total and glycosylated ferritin levels, although not pathognomonic, can help in diagnosis. The disease evolution of AOSD can be monocyclic, polycyclic or chronic. In chronic disease, joint involvement is often predominant and erosions are noted in one-third of patients. No prognostic factors have been identified to date. Therapeutic strategies are from observational data. Corticosteroids are usually the first-line treatment. With inadequate response to corticosteroids, methotrexate appears the best choice to control disease activity and allow for tapering of steroid use. For refractory disease, biological therapy with agents blocking interleukin-1 (anakinra) and then those blocking interleukin-6 (tocilizumab) seem the most promising.

Key words: anakinra, autoinflammatory syndrome, biologics, ferritin, glycosylated ferritin, inflammatory arthritides, Still disease

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1521-6942(08)00092-2

doi:10.1016/j.berh.2008.08.006

Best Practice & Research Clinical Rheumatology
Volume 22, Issue 5 , Pages 773-792, October 2008